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Abstract
Objective To evaluate diffusion kurtosis imaging (DKI) and
magnetisation transfer imaging (MTI) compared to standard
MRI for prostate cancer assessment in a re-biopsy population.
Methods Thirty-patients were imaged at 3 T including DKI
(Kapp and Dapp) with b-values 150/450/800/1150/1500 s/mm
2
and MTI performed with and without MT saturation. Patients
underwent transperineal biopsy based on prospectively de-
fined MRI targets. Receiver-operating characteristic (ROC)
analyses assessed the parameters andWilcoxon-signed ranked
test assessed relationships between metrics.
Results Twenty patients had ≥ 1 core positive for cancer in a
total of 26 MRI targets (Gleason 3+3 in 8, 3+4 in 12, ≥ 4+3 in
6): 13 peripheral (PZ) and 13 transition zone (TZ). The apparent
diffusion coefficient (ADC) and Dapp were significantly lower
and the Kapp andMTratio (MTR) significantly higher in tumour
versus benign tissue (all p ≤ 0.005); ROC values 0.767-1.000.
Normal TZ had: lower ADC and Dapp and higher Kapp and
MTR compared to normal PZ. MTR showed a moderate corre-
lation to Kapp (r = 0.570) and Dapp (r = -0.537) in normal tissue
but a poor correlation in tumours. No parameter separated low-
grade (Gleason 3+3) from high-grade (≥ 3+4) disease for either
PZ (p = 0.414-0.825) or TZ (p = 0.148-0.825).
Conclusion ADC, Dapp, Kapp and MTR all distinguished be-
nign tissue from tumour, but none reliably differentiated low-
from high-grade disease.
Key Points
• MTR was significantly higher in PZ and TZ tumours versus
normal tissue
• Kapp was significantly lower and Dapp higher for PZ and TZ
tumours
• There was no incremental value for DKI/MTI over mono-
exponential ADC parameters
• No parameter could consistently differentiate low-grade
(Gleason 3+3) from high-grade (≥ 3+4) disease
• Divergent MTR/DKI values in TZ tumours suggests they
offer different functional information
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Prostate cancer is the second leading cause of cancer in
men, accounting for around 20% of male cancer diagno-
ses [1]. The diagnosis of prostate cancer is primarily
based on transrectal ultrasound (TRUS)-guided biopsies.
However, this non-targeted sampling approach means
around a third of tumours will be under-graded and half
missed altogether [2, 3]. In patients with an initial nega-
tive biopsy, but continued clinical suspicion of prostate
cancer or suspicion of an under-sampled lesion, national
guidelines in the UK recommend further assessment to
exclude or confirm the presence of aggressive tumour
[4]. Multiparametric MRI (mpMRI) is used to guide re-
biopsy in such patients and has been shown to outperform
systematic TRUS biopsy for lesion detection [5].
However, studies report considerable variation in MRI
performance, with sensitivity and specificity ranging from
73-100% and 8-100%, respectively [6, 7], depending on
composition of the study population, radiologist experi-
ence, technical issues, and the gold standard employed.
Furthermore, specificity drops from 80% to 47% when
including indeterminate lesions, i.e. Prostate Imaging-
Reporting and Data System (PI-RADS) score 3 lesions
in addition to score 4-5 [6, 7]. This highlights the need
for improvement of existing sequences, or use of addition-
al functional sequences, with the most recent version of
the PI-RADS guidelines strongly supporting the contin-
ued development of further novel MRI sequences [8].
Here we study two imaging techniques in prostate can-
cer—diffusion kurtosis imaging (DKI) and magnetisation
transfer imaging (MTI). DKI is a novel technique for
studying the heterogeneity of water diffusion that has re-
cently been applied to the prostate, and MTI is a more
established technique for probing macromolecules in the
microenvironment, but there has been limited work using
this method in prostate cancer; neither approach requires
additional administration of exogenous contrast agents
and both could be translated into routine clinical practice
if effective.
DKI is a form of diffusion-weighted imaging that
quantifies the degree to which water diffusion in tissues
differs from what would be expected under a normal
(Gaussian) distribution of displacements, and from the
corresponding monoexponential decay of signal with in-
creasing b-value [9], deriving two parameters. The appar-
ent diffusivity Dapp quantifies the exponential component
of signal decay and is similar to the apparent diffusion
coefficient (ADC) in the standard mono-exponential mod-
el. The apparent kurtosis Kapp measures the first-order
deviation from mono-exponential decay and is thus a sim-
ple measurement of the deviation from a Gaussian distri-
bution of displacements. Theoretically, kurtosis values
may quantify the variability in tissue structure within the
region of interest, providing a measurement of intra-voxel
tissue heterogeneity, and may be useful for assessing
structural abnormalities in pathologic regions. Previous
studies have suggested a possible correlation between
Kapp and prostate cancer aggressiveness [10, 11], although
a recent large retrospective study showed that despite DKI
itself performing well, no added value was observed over
standard DWI sequences [12].
MTI detects the interaction between free and bound water
molecules. The Bfree^ pool consists of relatively mobile pro-
tons and provides the majority of the visible MR signal. The
Bbound^ pool incorporates the Bhydration layer^ of water
molecules bound to the surface of macromolecules. The pro-
tons associated with macromolecules are relatively immobile,
with decay times being too rapid to detect an MR signal [13],
however, the hydration layer is able to interact with the Bfree^
pool and can modulate its relaxation properties and affect the
measurable MR signal. This effect is exploited in MTI, where
an off-resonance radiofrequency pulse saturates the nuclear
magnetisation in the hydration layer; this in turn exchanges
with the free pool of protons and thus reduces the MR signal.
The MT ratio (MTR) is a simple derived metric and is there-
fore a measure of the structural integrity of tissues and can
probe the microstructural changes induced by pathological
processes [14].MTR has been shown to change inmalignancy
because of changes in cell number and size as well as changes
in cell membrane structures and extracellular space content,
which may help differentiate primary for secondary brain tu-
mours [15, 16]. Preliminary work in prostate cancer has dem-
onstrated a higher MTR within the peripheral zone of patients
with prostate cancer compared to normal controls [17, 18].
Advanced functional imaging with DKI and MTI may pro-
vide insight into the tissue structure and the complicated
micro-environment of prostate tumours. We therefore aimed
to evaluate whether the addition of these two novel MR quan-
tification parameters to standard MRI sequences could aid




Thirty-patients with a clinical suspicion of undiagnosed
prostate cancer were prospectively enrolled into this local
institutional review board-approved (CUH/13/EE/0100)
single-centre study between November 2013 and
June 2016, with all subjects signing written informed con-
sent. Inclusion criteria included prior negative biopsy with
a suspicious lesion on MRI (n = 24) or prior diagnosis of
low-grade prostate cancer and an MRI suspicious lesion
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in a remote gland location (n = 6). Patients subsequently
underwent MR-TRUS fusion template transperineal biop-
sy, including target cores from MRI suspicious lesion/s.
MR Imaging
All patients underwent 3-T MRI (MR 750, GE-Healthcare,
WI, USA) using a 32-channel phased-array coil. The pro-
tocol included multiplanar T2-weighted fast recovery fast
spin-echo (FSE) images of the prostate and axial T1-
weighted FSE images of the pelvis. Standard clinical axial
DWI was performed using a single spin-echo echo-planar
imaging (EPI) pulse sequence with b-values of 150/1000/
1400 s/mm2, with automated ADC maps. DCE was per-
formed as a 3D fast-spoiled gradient echo sequence; 85–
100 dynamic phases were acquired with temporal resolu-
tion 7 s; bolus gadobutrol (Schering AG) was injected in-
travenously via a power injector (rate 3 ml/s, dose
0.1 mmol/kg) followed by 25 ml saline flush; total scan
duration was 10 min.
DKI was performed as a single-shot dual-spin-echo EPI
pulse sequence, including five different b-values and a
‘noise-only’ image set with no RF pulses but otherwise
identical acquisition parameters. MTI volumes covering
the prostate were acquired with two 3D spoiled gradient
recalled-echo acquisitions with and without an MT satura-
tion pulse with slice thickness matched to T2-axial images.
The saturation pulse consisted of a 400° Fermi shape pulse
of 10-ms duration and 800 Hz bandwidth at 2.5 kHz off-
resonance frequency (Table 1).
MRI-Guided Biopsy
The MRIs were prospectively interpreted by one of two
uroradiologists with > 4 years’ prostate MRI reporting expe-
rience. Images were analysed according to PI-RADS version
1 criteria [19] prior to February 2015 (n = 13) and subsequent-
ly using criteria described in PI-RADS version 2 (n = 17) [4].
In all cases, interpretation was based on a Likert scale: 1, no
suspicious area; 2, cancer unlikely; 3, indeterminate; 4, cancer
likely; 5, cancer highly likely [19–22]. All studies were
reviewed in a multidisciplinary team environment, which in-
cluded radiologists, urologists, and oncologists, with all the
clinical information available prior to the decision to under-
take a biopsy. A positive lesion was defined as a Likert score ≥
3. DKI and MTR values did not inform biopsy decision-mak-
ing. The Biopsee™ MRI/TRUS-fusion biopsy system v.1 or
v.2 (Medcom, Darmstadt, Germany) was used for all biopsies.
A transrectal FlexFocus™ (BK-Medical, MA, USA) ultra-
sound probe was sited; the biplanar probe is fixed on a
stepping unit and sagittal prostate images aligned with MRI
using fusion software. Targets were prospectively drawn using
T2W as primary and ADC as secondary source images. All
patients underwent systematic transperineal biopsies
Table 1. Sequences in MRI
protocol Parameter Axial T2 2D
FSE
DWI DKI MTI
TR (ms) 3000-5000 4000 6000 24
TE (ms) 99-106 70–75 94 2.4 / 4.8
Averages 3 8 6 1
Section thickness
(mm)
3 4 3.6 4
Section gap (mm) 1 0 0.4 0
FOV (mm) 220 × 220 280 × 280 280 × 280 220 × 220
Matrix 384 × 288 128 × 128 128 × 96 192 × 160
Resolution (mm2) 0.6 × 0.8 2.2 × 2.2 2.2 × 2.9 1.15 × 1.38
Receiver bandwidth
(± kHz)
50 111 111 31
ASSET factor No ASSET 2 2 No
ASSET










FSE, fast spin echo; EPI, echo planar imaging; DWI, diffusion-weighted imaging; FOV, field of view; ETL, echo
train length; DKI, diffusion kurtosis imaging; MTI, magnetisation transfer imaging
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according to the Ginsburg protocol, using a spring-loaded 18-
G biopsy needle via a brachytherapy template grid [23]. In all
cases two biopsy cores were taken from each lesion(s) first,
with 24 background systematic biopsies subsequently ac-
quired. All procedures were performed by one of three urolo-
gists with several years’ experience of transperineal biopsy.
All biopsies were Gleason-graded by a specialist
uropathologist, following ISUP 2005 recommendations [24].
Image Analysis
Prospectively defined target outlines are stored on the local
PACS system during the clinical workflow. A fellowship-
trained uroradiologist with 7-years’ clinical prostate MR
reporting experience reviewed these original outlines and re-
drew freehand ROIs on T2-weighted axial images, avoiding
inclusion of the urethra or extra-prostatic tissue where rele-
vant, using in-house software programmed with MATLAB
(version 2016a; MathWorks, Natick, MA, USA). Additional
ROIs were drawn in regions of the biopsy-benign peripheral
zone (PZ) and transition zone (TZ) from the side contralateral
to the target over three consecutive slices, with a minimum
volume of 0.5 cm3. ROIs were secondarily transposed onto
ADC, DKI, and MTR maps; in cases with significant distor-
tion on any of the sequences, ROIs were adjusted to allow for
this, using the targets and prostate outline on T2-weighted
images for reference. DKI (Dapp and Kapp) and MTR param-
eter maps were calculated offline using custom software writ-
ten in Matlab. For DKI, the noise-only images were used to
reduce and partially compensate for noise-floor bias, which
could otherwise artificially enhance the kurtosis measurement
[10]. A small proportion of DKI fit-failure pixels were exclud-
ed. The mean ROI values of ADC, Dapp, and Kapp and MTR
maps were used for analysis.
Statistical analysis
Medians and ranges were used to summarise continuous var-
iables. Wilcoxon signed-rank test assessed the relationships
between parameters, benign versus tumour tissue, and tumour
grades in both the PZ and TZ. Receiver-operating character-
istic (ROC) analyses were used to assess the diagnostic utility
of metrics for detecting tumour and for discriminating
Gleason grade. An optimal threshold was determined for each
metric for discriminating tumour from benign tissue.
Pearson’s correlation assessed the relationship between the
metrics. All statistical analysis was performed in R (version
3.1.1, The R-Foundation, Austria); p < 0.05 was considered
statistically significant.
Results
Thirty patients were included, with a median age of 65.5 years
(range 50–76 years) and a median PSA of 7.67 ng/ml (IQR:
6.12-11.98 ng/ml). The median time from MRI to biopsy was
26 days (IQR: 7.25–48.25 days). Twenty-six patients had a
least one previous biopsy, with the interval from the most
recent biopsy to MRI being at least 3 months (median 13,
range 3-114, IQR 4–26 months).
Prostate cancer was detected in 24/30 patients including
targeted and background cores and in 20 patients within at
least one target core. In the four patients with only positive
background cores, all had a Gleason score (GS) 3+3 in 1-5%
of one core only. The remaining 20 patients had 26 separate
MRI lesions with positive target cores (4 patients with 2 tar-
gets, 1 with 3), of which 13 were in the peripheral zone (PZ)
and 13 in the transition zone (TZ) (Fig. 1). The final pathology
of the 26 targets was GS 3+3 (n = 8), 3+4 (12), 3+5 (1), 4+3
Fig. 1. Flow chart of biopsy
outcomes
Eur Radiol
(2), and ≥ 4+4 (3) (supplemental Table 1). The mean size for
these 26 targets was 1.16 cm2 (range 0.22 – 4.71 cm2).
Mean ADC and Dapp values for tumours in both the PZ and
TZ were significantly lower than comparative normal PZ and
Table 2. Target biopsy outcomes for MRI-defined lesions and contralateral benign tissue




ADC (× 10-3 mm2s-1)
Peripheral
zone
1.579 [1.363 – 1.794] 0.902 [0.869 – 0.974] N/A < 0.001* N/A
Transition
zone





2.221 [2.039 – 2.446] 1.167 [0.910 – 1.366] N/A < 0.001* N/A
Transition
zone




0.507 [0.426 – 0.550] 0.716 [0.621 – 0.869] N/A 0.004* N/A
Transition
zone




20.0 [15.5 – 22.9] 25.0 [24.0 – 28.1] N/A < 0.001* N/A
Transition
zone
26.9 [23.5 - 28.0] 30.0 [28.2 - 32.0] 15.2 [6.9 - 21.3] 0.005* < 0.001*
Mean values listed, interquartile range in parentheses; *p < 0.05. BPH, benign prostatic hyperplasia
Fig. 2. Peripheral zone target. A 64-year-old male with a PSA of 6.5 ng/
ml. Top row: clinical mpMRI sequences: T2w image (a), early time point
DCE image (b), and b = 1400 s/mm2 diffusion-weighted image (c).
Bottom row: assessed sequences: ADC map (d), Kapp (e), and MTR (f).
Target prospectively drawn in the right base PZ posteriorly (arrows). Note
calcification in the left base TZ (* in a) with corresponding artefact on all
other sequences. Target biopsy: 3 + 4 = 7 (35% pattern 4) in 60% cores
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TZ tissue (all P-values < 0.001) (Table 2). Conversely, mean
Kapp and MTR were significantly higher for PZ tumour and
TZ tumour compared to normal PZ and normal TZ (P ≤
0.005). Normal TZ had lower ADC and Dapp and higher
Kapp and MTR than normal PZ tissue, with cystic BPH dem-
onstrating higher ADC and Dapp and lower Kapp and MTR
compared to normal TZ (all P-values ≤ 0.005). For all mea-
sured parameters, there was a significant difference between
normal tissue and tumour and between cystic BPH and normal
TZ (all P ≤ 0.005).
ADC was able to distinguish tumour from benign tissue
with a sensitivity and specificity of 92.3% and 100% in the
PZ and 100% and 100% in the TZ, respectively. Kapp differ-
entiated tumour in the PZ with 76.9% sensitivity and 83.3%
specificity and in the TZ with 69.2% sensitivity and 100%
specificity. MTR distinguished tumour from benign tissue
with sensitivity and specificity of 76.9% and 86.7%, respec-
tively, in the PZ and 76.9% and 76.7%, respectively, in the TZ
(Figs. 2, 3 and 4). The ROC area-under-the-curve (AUC)
values from the diagnostic metrics ranged from 0.767 to
1.000 for separating tumour from benign tissue (Table 3,
Fig. 5). A comparison of AUCs using the bootstrapping meth-
od showed no statistically significant difference between
ADC and Dapp in the TZ or PZ (p = 1.0 and 0.670,
Fig. 3. Peripheral and transition zone target. A 69-year-old male with
PSA of 12.31 ng/ml. Top row: clinical mpMRI sequences: T2w image
(a), early time point DCE image (b), and b = 1400 s/mm2 diffusion-
weighted image (c). Bottom row: assessed sequences: ADC map (d),
Kapp (e), and MTR (f). Targets prospectively drawn in the anterior mid
gland TZ (outlines) and right mid PZ posteriorly (arrows). Both lesions
positive on Kapp and MTR maps; note clear zonal differentiation seen on
MTR maps. Target biopsy, PZ lesion: Gleason 3+4 in 2/2 cores 50%, up
to 8 mm; TZ lesion: Gleason 3+3 in 2/2 cores 50%, up to 4 mm
Fig. 4. Cystic BPH demonstrated by magnetisation transfer imaging. A
67-year-old patient, PSA 6.39 ng/ml; target biopsy shows Gleason 3+4
tumour in the left mid TZ (not shown). T2-weighted imaging (a) shows a
cystic area of BPH in the right apex transition zone (arrow); the area
appears as high signal withMT Bon^ imaging (b), isointense onMT Boff^
imaging (c), and low signal on the magnetization transfer ratio image (d)
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respectively). However, the diagnostic utility measured using
AUCs was significantly better for ADC compared to Kapp and
MTR in both the TZ (p = 0.036 and 0.007) and PZ (p = 0.028
and 0.014).
The ability of the parameters to distinguish low- (Gleason
3+3) from high-grade (Gleason ≥ 3+4) was also assessed. A
separate analysis was performed for PZ and TZ because of the
different values derived for normal tissue for all metrics. The
Gleason 3+3 group included four PZ and four TZ tumours; the
GS ≥ 3+4 included nine PZ and nine TZ tumours. All mea-
sured parameters were poor at separating low- and high-grade
disease for both PZ (p = 0.414-0.825) and TZ (p = 0.148-
0.825) (Table 4).
ADC showed a strong overall correlation to Dapp (r = -
0.862), as expected. ADC showed a moderate inverse corre-
lation to MTR (r = -0.618) and a good inverse correlation to
Kapp (r = -0.767) in normal tissue, with a lower correlation in
tumour tissue (r = -0.459 and -0.444, respectively) (Table 5).
MTR showed a moderate correlation to both Kapp (r = 0.570)
and Dapp (r = -0.537) in normal tissue, but conversely showed
a notably poor correlation to Kapp (r = 0.141) and Dapp (r = -
0.024) in tumour tissue.
Discussion
In this study we assessed the potential added value of
magnetisation transfer imaging and non-Gaussian diffusion
kurtosis imaging to conventional mpMRI sequences for the
detection of prostate cancer in a re-biopsy population, using
targeted transperineal biopsy as the reference standard. All
four measured parameters were able to distinguish benign
from tumour tissue, but performed poorly at differentiating
low- (GS 3+3) from high-grade (≥ 3+4) disease. Standard
diffusion-weighted imaging ADC maps showed a moderate
overall inverse correlation with both Kapp and MTR, but there
was no observable correlation between MTR maps and DKI
parameters within tumours.
A number of previous studies have looked at the ability of
DKI to differentiate tumour grade compared to standard
diffusion-weighted imaging with mono-exponential model-
ling. DKI parameters have repeatedly been shown to distin-
guish benign from tumour tissue, with several studies suggest-
ing that the kurtosis metric K outperforms ADC for differen-
tiating low- and high-grade tumours [10, 11, 25–27].
Table 3. Diagnostic utility of each respective metric in separating
normal tissue vs. tumour
Cut-off AUC Sensitivity (%) Specificity (%)
ADC × 10-3 mm2s-1
Transition zone 1.076 1.000 100.0 100.0
Peripheral zone 1.037 0.979 92.3 100.0
Dapp × 10
-3 mm2s-1
Transition zone 1.524 1.000 100.0 100.0
Peripheral zone 1.481 0.990 100.0 96.7
Kapp (unitless)
Transition zone 0.820 0.772 69.2 100.0
Peripheral zone 0.621 0.772 76.9 83.3
MTR (%)
Transition zone 28.2 0.767 76.9 76.7
Peripheral zone 24.0 0.828 76.9 86.7
AUC, area under the curve
Fig. 5. Receiver-operating characteristic curves of the performance of ADC, Dapp, Kapp, and MTR for differentiating benign tissue and tumour in the
peripheral (a) and transition zone (b)
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However, these studies also note a strong inverse correlation
between K with ADC, as supported by our data, raising the
question of the additional clinical benefit over existing DWI
sequences, given the increased technical complexity of DKI in
terms of post-processing and interpretation. Indeed, more re-
cent work and a large retrospective study using prostatectomy
as a reference standard suggested no additional benefit of DKI
sequences over conventional DWI [12, 28]. A possible expla-
nation is the use of a clinically derived ADC map in these
studies (using a high b-value of 1000) in contrast to earlier
work where the ADC map was derived from the DKI se-
quences with high b-values ranging from 1400-2000 s/mm2.
Current guidelines caution against using such high b-values
for ADC calculation because of the non-mono-exponential
decay and concerns about a reduced signal-to-noise ratio and
noise-floor bias [8]; this may therefore have affected the per-
formance of the ADC measurements in these studies. We also
derived ADC maps from standard clinical DWI sequences,
which may explain the lack of added benefit of DKI parame-
ters. Another explanation may be the longer echo time (TE)
used in the DKI sequence to achieve the diffusion weighting,
which reduced the intrinsic SNR of the Dapp obtained using
lower b-values, as suggested by Roethke et al. [28].
Two previous studies have investigated the utility of MTI
in prostate cancer [17, 18]. Both were performed at 1.5 T and
assessed only PZ tumours, used systematic TRUS biopsy as
the reference standard, and did not differentiate between
Gleason grades. Our results support the findings of these stud-
ies that normal TZ and PZ tumours have a higher MTR than
normal PZ. The difference in MTR between normal PZ and
normal TZ is expected given the difference in composition
between the tissue types: the lower value in the PZ may be
explained by a relatively loose stroma, a larger extracellular
space, and a fluid-filled glandular cavity [29]. The meanMTR
values derived here are comparable to those in the study by
Arima et al. [18] for both normal TZ (26.9% vs. 25.5%) and
PZ tumour (25.0% vs. 30.6%), but higher than the study by
Kumar et al. (7.01% and 8.29%, respectively) [17].
Conversely our results for normal PZ (20.0%) were much
higher than these two studies (8.0% and 6.15%, respectively).
This discrepancy may relate to the fact that MTR is an arbi-
trary measure and depends on the characteristics of the pulse
sequence; the Kumar et al. study differed from ours in being a
2D sequence with a long TR. In addition, the earlier studies
may have effects relating to residual post-biopsy haemor-
rhage, which will predominantly affect the PZ rather than
the TZ when systematic TRUS biopsy is performed, but will
typically be excluded from areas containing cancer [30]; thus
only normal PZ rather than TZ or PZ tumour will be affected.
A number of previous studies have shown ADC to de-
crease as tumour Gleason grade increases, albeit with a degree
of overlap in values between tumour grades [31–33].
Table 4. Ability of metrics to
distinguish low- (Gleason 3+3)
from high-grade (Gleason ≥ 3+4)
tumours
Gleason 3+3 Gleason ≥ 3+4 p-value
Peripheral zone n = 4 n = 9
ADC× 10-3 mm2s-1 0.905 [0.860 – 0.949] 0.902 [0.893 – 0.1036] 0.711
Dapp × 10
-3 mm2s-1 1.275 [1.047 – 1.463] 1.167 [0.740 – 1.196] 0.414
Kapp (unitless) 0.759 [0.643 – 0.902] 0.716 [0.480 – 0.867] 0.711
MTR (%) 26.1 [23.4 – 28.4] 25.0 [24.0 – 27.5] 0.825
Transition zone n = 4 n = 9
ADC× 10-3 mm2s-1 0.881 [0.864 – 0.887] 0.830 [0.799 – 0.884] 0.414
Dapp × 10
-3 mm2s-1 0.926 [0.889 – 0.979] 1.006 [0.745 – 1.083] 0.825
Kapp (unitless) 0.695 [0.508 – 0.924] 0.975 [0.820 – 1.035] 0.414
MTR (%) 31.9 [31.3 – 32.2] 29.6 [26.3 – 31.5] 0.148
Mean values listed, interquartile range in parentheses
Table 5. Correlation between
assessed metrics (Pearson’s Rho) Comparators Tumour Tissue (TZ +
PZ)
Normal Tissue (TZ +
PZ)
Normal + Tumour Tissue (TZ +
PZ)
ADC vs Kapp -0.444 -0.767 -0.641
ADC vs Dapp -0.041 -0.790 0.862
ADC vs MTR -0.459 -0.618 -0.633
Kapp vs Dapp 0.646 -0.532 -0.359
Kapp vs MTR 0.141 0.570 0.429
Dapp vs MTR -0.024 -0.537 -0.531
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Although there was a trend for lower ADC values in higher-
grade (Gleason ≥ 3+4) tumours in our cohort, this was non-
significant, which may relate to the relatively small sample
size, particularly within the PZ. However, the concordance
between ADC and Gleason grade has recently been
questioned [34], with the demonstration that Gleason 3+3 tu-
mours can have low ADC values [35]. This highlights the
need for further work in the area to both improve the under-
standing of ADC metrics in this regard and assess additional
better functional sequences for characterisation of tumour ag-
gressiveness. MTR showed a moderately strong correlation to
both Kapp (r = 0.57) and Dapp (r = -0.537) in normal tissue, yet
no correlation in tumour tissue (r = 0.141 and -0.024, respec-
tively). Of note, there was a non-significant trend for increas-
ing Kapp, but conversely lowerMTR in higher-grade transition
zone tumours. These divergent results combined with the poor
correlation of MTI and DKI suggest that the techniques offer
different but complementary information on the tumour mi-
croenvironment. Interestingly, both tumour Kapp and MTR
showed a high inverse correlation to ADC (r = -0.444 and -
0.459, respectively), suggesting that cellularity is partly con-
tributing to these metrics, whilst other factors are contributing
to their divergent values. At higher Gleason grades, the glan-
dular structure of the prostate is progressively disrupted with
increased cellularity and a reduction in the stromal matrix and
luminal space [21]. This increased heterogeneity can therefore
help to explain a trend for higher Kapp values observed in
higher-grade tumours [10]. Higher-grade prostate cancer is
expected to result in an increased number of intracellular
bound water molecules due to increased cellular density
[36]; however, this is counteracted by a breakdown of the
normal extensive extracellular matrix [37]. These competing
processes may provide an explanation for the divergence
among DWI, DKI, and MTI demonstrated here in tumours.
Our study has a number of limitations. The numbers within
the cohort were relatively low; this may have particularly af-
fected attempts to differentiate high- and low-grade tumours,
where further sub-division became necessary. Targeted biopsy
ensured that tissue was sampled from the outlined lesion;
however, as with any biopsy technique, this is prone to sam-
pling error and may misclassify the grade compared to the
more robust gold standard of prostatectomy [38]. Targets were
prospectively chosen based on clinical mpMRI sequences,
and DKI/MTR values were not used to inform the biopsy
decision. This may have led to a bias towards lesions with
restricted diffusion and low ADC, particularly within the PZ
where this is considered the key diagnostic sequence.
Conversely, there may be a bias against areas that demonstrat-
ed changes on DKI or MTR but not on conventional MRI
sequences as they would not have been biopsied.
In conclusion, ADC, MTI, and DKI readily distinguished
benign tissue from tumour, but none of the measured param-
eters reliably differentiated low- from high-grade disease.
Differences between DKI and MTI at higher Gleason grades
may be explained by changes in the cellularity, stromal matrix,
and luminal space. DKI andMTI may therefore offer different
but potentially complementary information on the tumour
microenvironment.
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